Abstract
A clinical trial was conducted with Alice/R-75 strain live attenuated intranasal influenza A/B vaccine. With double blind control 88 adult volunteers were administered 2 doses of Alice/R-75 vaccine, 93 volunteers received one dose of Alice/R-75 vaccine and one dose placebo solution and 94 subjects were administered 2 doses of placebo solution. Twenty-three other subjects received Alice strain monovalent influenza A vaccine. For comparison, data from 21 subjects who received monovalent intranasal R-75 strain influenza B in two doses is included. The vaccine was generally well tolerated. Four-fold serum hemagglutination-inhibiting (HAI) antibody titer rises to A/England/42/72 occurred in 39% of the monovalent Alice strain vaccinees; in contrast 18% of those given 2 doses of bivalent Alice/R-75 vaccine and 11% of those given 1 dose of bivalent vaccine had similar four-fold HAI antibody titer rises. HAI antibody titer rises to influenza B/Hong Kong/72 occurred in 38% of R-75 strain monovalent vaccinees, 14% of Alice/R-75 2-dose vaccinees and 11% of Alice/R-75 one dose vaccinees. An epidemic of influenza at the onset of the study made evaluation of the efficacy of the vaccine impossible.
Similar content being viewed by others
References
Beare, A.S., Bynoe, M.L.: Attenuation of human influenza A viruses. Brit. Med. J.1969 IV, 198–201
Beare, A.S., Hobson, D., Reed, S.E., et al.: A comparison of live and killed influenza virus vaccines. Lancet1968 II, 418–420
Beare, A.S., Schild, G.C., Craig, J.W.: Trials in man with live recombinants made from A/PR/8/34 (NO N1) and wild H3N2 influenza viruses. Lancet (1975)II, 1–10
Beare, A.S., Sherwood, J.E., Callow, K.A., et al.: Selection of influenza B virus recombinants and their testing in humans for attenuation and immunogenicity. Infect. Immunity.15, 347–353 (1977)
Donaldson, A., Winsor, H.J., Bennett, N.M., et al.: Studies with a live influenza A vaccine in army personnel. Pathology9, 49–56 (1977)
Douglas, R.G., Jr., Bentley, D.W., Betts, R.F., et al.: Evaluation of a temperature-sensitive influenza virus in elderly and chronically ill subjects. Amer. Rev. Resp. Dis.113, 293–300 (1976)
Evans, A.E.J., Letley, E., Ferris, R.D., et al.: WRL strain live attenuated influenza vaccine; comparison of one and two dose schedules. J. Hyg. Camb.77, 327–332 (1976)
Freestone, D.S., Bowker, C.H., Letley, E., et al.: A clinical trial of WRL 105 strain live attenuated influenza vaccine comparing four methods of intranasal vaccination. J. Hyg. Camb.76, 459–466 (1976)
Hall, C.B., Douglas, R.G., Jr., Fralonardo, S.A.: Live attenuated influenza virus vaccine trial in children. Pediatrics56, 991–998 (1975)
Hall, W.J., Douglas, R.G., Jr., Zaky, D.A., et al.: Attenuated influenza virus in normal adults: Role of pulmonary function studies in vaccine trials. J. Infect. Dis.133, 145–152 (1976)
Kilbourne, E.D.: New approaches to the prevention of influenza. Acta Medica Scand.25, 45–48 (1975)
Kilbourne, E.D., Butler, W.T., Rossen, R.D.: Specific immunity in influenza — Summary of influenza workshop III. J. Infect. Dis.127, 220–236 (1973)
Kilbourne, E.D., Chanock, R.M., Choppin, P.W., et al.: Influenza vaccines — Summary of influenza workshop V. J. Infect. Dis.129, 750–771 (1974)
Lauteria, S.F., Kantzler, G.B., High, P.C., et al.: An attenuated influenza virus vaccine: Reactogenicity, transmissibility, immunogenicity, and protective efficacy. J. Infect. Dis.130, 380–383 (1974)
Lee, J.D., Khakoo, R.A., Stree, C.K., et al.: An attenuated influenza virus vaccine: Protection against homologous and heterologous strains of virus. J. Infect. Dis.135, 824–827 (1977)
Maassab, H.F., Francis, T., Jr., Davenport, F.M., et al.: Laboratory and clinical characteristics of attenuated strains of influenza virus. Bull. Org. Mond. Sante Bull. Wld. Hlth. Org.41, 589–594 (1969)
Mackenzie, J.S., Mackenzie, I., Lloyd, J., et al.: Comparative trials of live attenuated and detergent split influenza virus vaccines. J. Hyg.75, 425–442 (1975)
Miller, L.W., Hume, D.B., O'Brien, F.R., et al.: Alice strain live attenuated influenza (H3N2) vaccine in an elderly population. Amer. J. Epidemiol.101, 340–346 (1975)
Miller, L.W., Togo, Y., Hornick, R.B.: Clinical and serologic effects of Alice strain live attenuated influenza A (H3N2) virus vaccine in an adult population. Med. Microbiol. Immunol.162, 14–21 (1975)
Minor, T.E., Dick, E.C., Dick, C.R., et al.: Attenuated influenza A vaccine (Alice) in an adult population: Vaccine-related illness, serum and nasal antibody production, and intrafamily transmission. J. Clin. Microbiol.2, 403–409 (1975)
Moffat, M.A.J., Stealey, V.M., Freestone, D.S., et al.: Assessment of elicted antibody responses, clinical reactions and transmissibility of WRL 105 live influenza vaccine. J. Biol. Standard.4, 91–95 (1976)
Morris, C.A., Freestone, D.S., Stealey, V.M., et al.: Comparison of antibody responses and reactivity of “Alice” and WRL 105 strain live influenza vaccines. Lancet (1976)I, 1118–1120
Murphy, B.R., Chalhub, E.G., Nusinoff, S.R., et al.: Temperature-sensitive mutants of influenza virus, III. Further characterization of the ts-1 [E] influenza A recombinant (H3N2) virus in man. J. Infect. Dis.128, 479–487 (1973)
Prevost, J.M., Vereerstraeten-Schmerber, J., Lamy, F., et al.: Live attenuated influenza virus vaccines in patients with chronic bronchopulmonary diseases. Scand. J.Resp. Dis.56, 58–59 (1975)
Rytel, M.W., Jackson, L.J., Ferstenfeld, J.E., et al.: New live attenuated influenza A/England/42/72 (H3N2) vaccine (Alice): Reactogenicity, immunogenicity, and protection efficacy. J. Infect. Dis.132, 652–659 (1975)
Rytel, M.W., Jackson, J., Niebojewski, R.A., et al.: Field trial of live attenuated influenza A/B (“Alice”/R-75) vaccine. Amer. J. Epidemiol.105, 49–55 (1977)
Schiff, G.M., Linnemann, C.C., Jr., Shea, L., et al.: Evaluation of a live, attenuated recombinant influenza vaccine in high school children. Infect. Immunity11, 754–757 (1975)
Smorodintsev, A.A.: New live vaccines against virus diseases. Amer. J. Public Health50, 40–45 (1960)
Spencer, M.J., Cherry, J.D., Powell, K.R., et al.: Clinical trials with Alice strain, live, attenuated, serum inhibitor-resistant intranasal influenza A vaccine. J. Infect. Dis.132, 415–419 (1975)
Spencer, M.J., Cherry, J.D., Powell, K.R.: Clinical trial with “R-75” strain live, attenuated, serum inhibitor-resistant intranasal influenza B vaccine. J. Clin. Microbiol.5, 584–587 (1977)
Zeck, R., Solliday, N., Kehoe, T., et al: Respiratory effects of live influenza virus vaccine: Health older subjects and patients with chronic respiratory disease. Amer. Rev. Resp. Dis.114, 1061–1067 (1976)
Author information
Authors and Affiliations
Additional information
This study was supported by a grant from Smith, Kline and French Laboratories, Philadelphia, Pennsylvania
Rights and permissions
About this article
Cite this article
Spencer, M.J., Cherry, J.D., Powell, K.R. et al. A clinical trial with Alice/R-75 strain, live attenuated serum inhibitor-resistant intranasal bivalent influenza A/B vaccine. Med Microbiol Immunol 167, 1–9 (1979). https://doi.org/10.1007/BF02123290
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02123290